|
1
|
Maire G, Martin JW, Yoshimoto M,
Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of
miRNA-gene expression-genomic profiles reveals complex mechanisms
of microRNA deregulation in osteosarcoma. Cancer Genet.
204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcomaPediatric and Adolescent Osteosarcoma. Jaffe N,
Bruland OS and Bielack S: Springer; New York: pp. 3–13. 2010
|
|
3
|
Kobayashi E, Hornicek FJ and Duan Z:
MicroRNA involvement in osteosarcoma. Sarcoma. 2012:3597392012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leithner A, Maurer-Ertl W, Glehr M,
Friesenbichler J, Leithner K and Windhager R: Wikipedia and
osteosarcoma: A trustworthy patients' information? J Am Med Inform
Assoc. 17:373–374. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ternovoi VV, Curiel DT, Smith BF and
Siegal GP: Adenovirus-mediated p53 tumor suppressor gene therapy of
osteosarcoma. Lab Invest. 86:748–766. 2006.PubMed/NCBI
|
|
6
|
Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs
JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G and Li TF:
Inhibition of the Wnt-β-catenin and Notch signaling pathways
sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res
Commun. 431:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ando K, Mori K, Corradini N, Redini F and
Heymann D: Mifamurtide for the treatment of nonmetastatic
osteosarcoma. Expert Opin Pharmacother. 12:285–292. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferguson WS, Harris MB, Goorin AM,
Gebhardt MC, Link MP, Shochat SJ, Siegal GP, Devidas M and Grier
HE: Presurgical window of carboplatin and surgery and multidrug
chemotherapy for the treatment of newly diagnosed metastatic or
unresectable osteosarcoma: Pediatric Oncology Group Trial. J
Pediatr Hematol Oncol. 23:340–348. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jaffe N: Osteosarcoma: Review of the Past,
Impact on the Future. The American ExperiencePediatric and
Adolescent Osteosarcoma. Jaffe N, Bruland OS and Bielack S:
Springer; NY: pp. 239–262. 2010
|
|
10
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cross D and Burmester JK: Gene therapy for
cancer treatment: Past, present and future. Clin Med Res.
4:218–227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang YW, Morita I, Ikeda M, Ma KW and
Murota S: Connexin43 suppresses proliferation of osteosarcoma U2OS
cells through post-transcriptional regulation of p27. Oncogene.
20:4138–4149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma X, Yang Y, Wang Y, An G and Lv G: Small
interfering RNA-directed knockdown of S100A4 decreases
proliferation and invasiveness of osteosarcoma cells. Cancer Lett.
299:171–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang K, Tian F, Zhang Y, Zhu Q, Xue N,
Zhu H, Wang H and Guo X: MACC1 is involved in the regulation of
proliferation, colony formation, invasion ability, cell cycle
distribution, apoptosis and tumorigenicity by altering Akt
signaling pathway in human osteosarcoma. Tumor Biol. 35:2537–2548.
2014. View Article : Google Scholar
|
|
15
|
Reiche D, Pfannkuche H, Michel K, Hoppe S
and Schemann M: Immunohistochemical evidence for the presence of
calbindin containing neurones in the myenteric plexus of the
guinea-pig stomach. Neurosci Lett. 270:71–74. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parmentier M, Passage E, Vassart G and
Mattei MG: The human calbindin D28k (CALB1) and calretinin (CALB2)
genes are located at 8q21.3----q22.1 and 16q22----q23,
respectively, suggesting a common duplication with the carbonic
anhydrase isozyme loci. Cytogenet Cell Genet. 57:41–43. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CT, Huynh VM, Lai LW and Lien YH:
Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout
and wild-type mice. Kidney Int. 62:2055–2061. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Margolis DS, Kim D, Szivek JA, Lai LW and
Lien YH: Functionally improved bone in calbindin-D28k knockout
mice. Bone. 39:477–484. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rabinovitch A, Suarez-Pinzon WL, Sooy K,
Strynadka K and Christakos S: Expression of calbindin-D28k in a
pancreatic Isletβ-Cell line protects against cytokine-induced
apoptosis and necrosis. Endocrinology. 142:3649–3655. 2001.
View Article : Google Scholar
|
|
20
|
Liu Y, Porta A, Peng X, Gengaro K,
Cunningham EB, Li H, Dominguez LA, Bellido T and Christakos S:
Prevention of Glucocorticoid-Induced Apoptosis in Osteocytes and
Osteoblasts by Calbindin-D28k. J Bone Miner Res. 19:479–490. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bellido T, Huening M, Raval-Pandya M,
Manolagas SC and Christakos S: Calbindin-D28k is expressed in
osteoblastic cells and suppresses their apoptosis by inhibiting
caspase-3 activity. J Biol Chem. 275:26328–26332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sottnik JL, Campbell B, Mehra R,
Behbahani-Nejad O, Hall CL and Keller ET: Osteocytes serve as a
progenitor cell of osteosarcoma. J Cell Biochem. 115:1420–1429.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trieb K, Lehner R, Stulnig T, Sulzbacher I
and Shroyer KR: Survivin expression in human osteosarcoma is a
marker for survival. Eur J Surg Oncol. 29:379–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katsetos CD, Herman MM, Krishna L, Vender
JR, Vinores SA, Agamanolis DP, Schiffer D, Burger PC and Urich H:
Calbindin-D28k in subsets of medulloblastomas and in the human
medulloblastoma cell line D283 Med. Arch Pathol Lab Med.
119:734–743. 1995.PubMed/NCBI
|
|
27
|
Castro CY, Stephenson M, Gondo MM,
Medeiros LJ and Cagle PT: Prognostic implications of calbindin-D28k
expression in lung cancer: Analysis of 452 cases. Mod Pathol.
13:808–813. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang K, Fu W, Beardsley AR, Sun X, Lisanti
MP and Liu J: Overexpression of caveolin-1 inhibits endothelial
cell proliferation by arresting the cell cycle at G0/G1 phase. Cell
Cycle. 6:199–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang T, Hao L, Feng Y, Wang G, Qin D and
Gu G: Knockdown of MED19 by lentivirus-mediated shRNA in human
osteosarcoma cells inhibits cell proliferation by inducing cell
cycle arrest in the G0/G1 phase. Oncol Res. 19:193–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang JS, Ji AF, Wan HJ, Lu YL, Yang JZ, Ma
LL, Wang YJ and Wei W: Gene Silencing of ß-catenin by RNAi inhibits
proliferation of human esophageal cancer cells by inducing G0/G1
cell cycle arrest. Asian Pac J Cancer Prev. 13:2527–2532. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ning S, Fuessel S, Kotzsch M, Kraemer K,
Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A:
siRNA-mediated down-regulation of survivin inhibits bladder cancer
cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
|
|
34
|
Høj BR, la Cour JM, Mollerup J and
Berchtold MW: ALG-2 knockdown in HeLa cells results in G2/M cell
cycle phase accumulation and cell death. Biochem Biophys Res
Commun. 378:145–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rintoul GL, Raymond LA and Baimbridge KG:
Calcium buffering and protection from excitotoxic cell death by
exogenous calbindin-D28k in HEK 293 cells. Cell calcium.
29:277–287. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Christakos S and Liu Y: Biological actions
and mechanism of action of calbindin in the process of apoptosis. J
Steroid Biochem Mol Biol. 89–90:401–404. 2004. View Article : Google Scholar
|
|
38
|
Sun S, Li F, Gao X, Zhu Y, Chen J, Zhu X,
Yuan H and Gao D: Calbindin-D28K inhibits apoptosis in dopaminergic
neurons by activation of the PI3-kinase-Akt signaling pathway.
Neuroscience. 199:359–367. 2011. View Article : Google Scholar : PubMed/NCBI
|
